NewSquare Capital’s Metacrine, Inc. Common Stock MTCR Stock Holding History

NewSquare Capital’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-600	Closed	-$269	–	969
2022 Q4	$269	Buy	+600	New	+$248	﹤0.01%	712

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

NewSquare Capital's MTCR Position: Q1 2023 in Review

NewSquare Capital sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 600 shares — an estimated $269 sold.

NewSquare Capital first reported a position in MTCR in Q4 2022 and held it in 1 quarter. The position peaked at $269 in Q4 2022. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

NewSquare Capital reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
NewSquare Capital sold 600 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $269.
NewSquare Capital first reported a position in Metacrine, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
NewSquare Capital's Metacrine, Inc. Common Stock position peaked at $269 in Q4 2022.
5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on NewSquare Capital's 13F filing for Q1 2023, filed 1 May 2023.